Ryvu Therapeutics (LTS:0RKT) Cyclically Adjusted Book per Share: zł15.46 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł86.63
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Cyclically Adjusted Book per Share?

Ryvu Therapeutics LTS:0RKT 66 Cyclically Adjusted Book per Share is zł15.46 as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ryvu Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was zł1.787. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is zł15.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ryvu Therapeutics's average Cyclically Adjusted Book Growth Rate was 1.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Ryvu Therapeutics was 18.60% per year. The lowest was 11.10% per year. And the median was 14.85% per year.

As of today (2026-07-17), Ryvu Therapeutics's current stock price is zł30.25. Ryvu Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was zł15.46. Ryvu Therapeutics's Cyclically Adjusted PB Ratio of today is 1.96.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ryvu Therapeutics was 10.64. The lowest was 1.20. And the median was 5.05.


Ryvu Therapeutics  (LTS:0RKT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ryvu Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=30.25/15.46
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ryvu Therapeutics was 10.64. The lowest was 1.20. And the median was 5.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ryvu Therapeutics Cyclically Adjusted Book per Share Related Terms


Ryvu Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Cyclically Adjusted Book per Share Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 10.59 12.62

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.81 10.69 12.37 12.62 15.46

LTS:0RKT vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Cyclically Adjusted PB Ratio falls into.


LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ryvu Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.787/163.0700*163.0700
=1.787

Current CPI (Mar. 2026) = 163.0700.

Ryvu Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.515 99.552 5.758
201609 3.733 99.064 6.145
201612 4.119 100.366 6.692
201703 4.577 101.018 7.389
201706 4.669 101.180 7.525
201709 4.757 101.343 7.654
201712 4.524 102.564 7.193
201803 13.273 102.564 21.103
201806 13.013 103.378 20.527
201809 13.318 103.378 21.008
201812 10.665 103.785 16.757
201903 11.544 104.274 18.053
201906 11.004 105.983 16.931
201909 10.561 105.983 16.250
201912 7.550 107.123 11.493
202003 7.280 109.076 10.884
202006 7.011 109.402 10.450
202009 12.785 109.320 19.071
202012 11.830 109.565 17.607
202103 11.450 112.658 16.574
202106 10.516 113.960 15.048
202109 9.715 115.588 13.706
202112 8.788 119.088 12.034
202203 8.228 125.031 10.731
202206 6.659 131.705 8.245
202209 6.217 135.531 7.480
202212 18.708 139.113 21.930
202303 14.221 145.950 15.889
202306 13.118 147.009 14.551
202309 12.383 146.113 13.820
202312 11.228 147.741 12.393
202403 8.448 149.044 9.243
202406 8.884 150.997 9.594
202409 7.689 153.439 8.172
202412 6.587 154.660 6.945
202503 5.174 157.021 5.373
202506 4.119 157.509 4.264
202509 3.081 158.000 3.180
202512 2.328 158.320 2.398
202603 1.787 163.070 1.787

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of zł15.46 mean?
Ryvu Therapeutics (LTS:0RKT) has a Cyclically Adjusted Book per Share of zł15.46 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Cyclically Adjusted Book per Share too high?
Ryvu Therapeutics' current Cyclically Adjusted Book per Share is zł15.46. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Cyclically Adjusted Book per Share compare to VRTX and REGN?
Ryvu Therapeutics' Cyclically Adjusted Book per Share of zł15.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Cyclically Adjusted Book per Share is zł15.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Cyclically Adjusted Book per Share of zł15.46. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current Cyclically Adjusted Book per Share is zł15.46. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Cyclically Adjusted Book per Share is zł15.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.

Key valuation signals for LTS:0RKT:

  • Cyclically Adjusted Book per Share: zł15.46
  • GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł86.63
GF Value